Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Budesonide + levosalbutamol hydrochloride is a fixed-dose combination inhalation therapy used primarily for the management of asthma and chronic obstructive pulmonary disease (COPD). It combines two active ingredients with complementary mechanisms: - Budesonide is an inhaled corticosteroid that reduces inflammation in the airways, helping to prevent and control symptoms such as wheezing, coughing, and shortness of breath. - Levosalbutamol hydrochloride (also known as levalbuterol) is a selective beta2-adrenoceptor agonist bronchodilator that relaxes airway smooth muscle, providing rapid relief from bronchospasm. This dual-action approach offers both immediate symptom relief (via bronchodilation) and long-term control of airway inflammation. The medication is typically administered via nebulizer or specialized inhalation devices. Common side effects may include throat irritation, cough, headache, tremor, increased heart rate, and oral candidiasis[1][2][3][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on budesonide + levosalbutamol hydrochloride.